The Future of Cancer Treatment: Cutting-Edge Advances in Immuno-Oncology
November 8, 2024
Imagine a future where cancer treatment is as precise and personalized as it is powerful, where the body’s own defenses are guided to hunt down and destroy tumors. This vision is becoming reality through immuno-oncology (IO), a transformative field empowering the immune system to selectively attack cancer cells. Unlike traditional treatments like chemotherapy and radiation, […]
GSK’s $300M Acquisition of Chimagen’s CMG1A46: A Deep Dive into B Cell-Targeted Trispecific T Cell Engagers
November 4, 2024
On October 29, GSK made headlines with a $300 million upfront payment to acquire Chimagen Biosciences’ clinical-stage asset, CMG1A46, a dual-target CD19/CD20 trispecific T cell engager (TCE). This acquisition signals GSK’s commitment to advancing therapies for B-cell-driven autoimmune diseases, such as systemic lupus erythematosus and lupus nephritis, with possible applications in other autoimmune conditions. B […]
Research Impact: B-NDG Mice Used to Identify Lipid Transport Mechanism Driving T Cell Leukemogenesis
September 29, 2022
By John Charpentier, Ph.D. September 29, 2022 A recent study featuring Biocytogen mice identifies a non-vesicular lipid transport mechanism required for T cell leukemogenesis. Wenbing Zhong and colleagues at Jinan University in Guangzhou, China report that a lipid binding protein called ORP4L, which is expressed in adult T cell leukemia (ATL) cells but not normal […]
